

UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 90,1092-BBB)

PATENT

In the Application of: )

Civelli et al. )

Serial No. 09/934,358 )

Filed: August 21, 2001 )

For: Dopamine Receptor and Uses )

Group Art Unit: 1646

Examiner: J. Ulm

RECEIVED  
TECH CENTER 1600/2900  
03 FEB - 3 PM 12:40

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached Information Disclosure Statement, Form PTO-1449 and cited references.
2. With respect to additional fees:
  - A. X No additional fee is required.
  - B. \_\_\_ An additional fee is required and has been calculated as shown below:
  - C. \_\_\_ Attached is a check in the amount of \$ \_\_\_\_\_.
  - D. \_\_\_ Charge the total additional fee to our Deposit Account No. **13-2490**.  
A duplicate copy of this sheet is enclosed.
3. Please charge any additional fees or credit overpayment to Deposit Account No. **13- 2490**.  
A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being hand delivered Examiner J. Ulm in Group Art Unit 1646; at Commissioner for Patents, Washington, D.C. 20231 on this 31<sup>st</sup> day of January, 2003.

Date: January 31, 2003

By:

Kevin E. Noonan  
Reg. No. 35,303

UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 90,1092-BBB)

PATENT

In the Application of:

Civelli et al.

Serial No. 09/934,358

Filed: August 21, 2001

For: Dopamine Receptor and Uses

Group Art Unit: 1646

Examiner: J. Ulm

RECEIVED  
TECH CENTER 1600/2900  
03 FEB - 3 PM 12:40

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,  
McDonnell Boehnen Hulbert & Berghoff

Date: January 31, 2003

Kevin E. Noonan  
Reg. No. 35,303

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce**  
**Patent and Trademark Office**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use several sheets if necessary)

**Atty. Docket No.**

90,1092-BBB

**Serial No.**

09/934,358

**Applicant:**

Civelli et al.

**Filing Date:**

August 21, 2001

**Group:**

1646

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	4,761,371	8/2/98	Bell, et al.			
	4,683,195	7/28/87	Mullis, et al.			
	4,683,202	11/27/90	Mullis, et al.			
	4,599,308	7/8/86	Hamer, et al.			
	4,650,764	3/17/87	Temin, et al.			
	4,861,719	8/29/89	Miller			
	5,422,265	6/6/95	Civelli			
	5,569,601	10/29/96	Civelli			
	5,880,260	3/9/99	Civelli			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
WO 92	/ 1 0 5 7 1	6/25/92					
WO 91	/ 1 2 3 3 9	8/22/91					
WO 94	/ 0 3 6 0 2	2/19/94					

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

		Ackenheil, et al., "Antipsychotische Wirksamkeit im Verhalten zum Plasmaspiegel von Clozapin," <i>Arzneim-Forsch</i> 26, 1156-1158 (1976)
		Albert (1984) <i>J. Biol Chem.</i> 259:15350-15363
		Amlaiky and Caron, "Identification of the D2-Dopamine Receptor Binding Subunit in Several Mammalian Tissues and Species by Photoaffinity Labeling," <i>J. Neurochem.</i> 47, 196-204 (1986)
		Abramson, <i>Biochem Pharmacol</i> 37:4289-4297 (1988)
		Amlaiky and Caron, "Photoaffinity Labeling of the D2-dopamine Receptor Using a Novel High Affinity Radioiodinated Probe," <i>J. Biol Chem.</i> 260, 1983-1986 (1985)
		Amlaiky, et al., "Identification of the Binding Subunit of the D1-Dopamine Receptor by Photoaffinity Crosslinking," <i>Mol. Pharmacol.</i> 31, 129-134 (1987)
		Barnes D.M. <i>Science</i> 241, 415-417 (1988)
		Ben-Jonathon (1977) <i>Endocrinology</i> 100:452-458
		Bertling, "Transfection of a DNA/Protein Complex into Nuclei of Mammalian Cells Using Polyoma Capsides and Electroporation," <i>Bioscience Reports</i> 7, 107112 (1987)
		Borgundbvaag V. <i>Life Sci.</i> 37:379-386 (1985)
		Botstein, et al., "Construction of a Genetic Linkage Map in Man Using Restriction fragment Length Polymorphisms," <i>Am. J. Hum. Genet.</i> 32, 314-331 (1980)
		Bouvier, et al., "Removal of phosphorylation sites from the $\beta_2$ -adrenergic receptor delays onset of agonist-promoted desensitization," <i>Nature</i> 333, 370-373 (1988)
		Boyson, <i>Neurosci.</i> 6, 3177-3188 (1986)
		Bunney B.S. (1973) <i>Nature (New Biol)</i> 245:123-125
		Bunzow, et al., "Cloning and expression of a rat D2 dopamine receptor cDNA," <i>Nature</i> 336, 783,787 (1988)
		Canonico P.L. (1986) <i>J. Endocrinol</i> 110:389-393
		Casey, "Clozapine: neuroleptic-induced EPS and tardive dyskinesia," <i>Psychopharmacology</i> 99, S47-S53 (1989)
		Cole T.E., <i>J. Neural. Trans. Suppl.</i> 18, 139-147 (1983)
		Cote, <i>J. Neural Trans Suppl.</i> 18:139-147 (1983)
		Cheng, <i>Biochem Pharmacol</i> 22, 3099-3108 (1973)
		Cooper, et al., "Catecholamines II: CNS Aspects," in <i>The Biochemical Basis of Neuropharmacology</i> , 3d ed. 1978 (Oxford University Press, N.Y.), pp. 161-195
		Crease, et al., <i>European J. Pharmacol.</i> 45:(1977) 377-381
		Crease I., <i>Ann. Rev. Neurosci.</i> 6, 43-71 (1983)
		Cronin (1983) <i>Am. J. Physiol</i> 244:E499-E504
		Dal Toso, et al. <i>EMBO J.</i> 8, 4025-4034 (1989)
		DeCamilli P., (1979) <i>Nature</i> 278:252-254
		Dixon., <i>Nature</i> 321, 75-79 (1986)

			Dorflinger, (1983) Endocrinology 113:1541-1500, 1551-1558
			Drouva S. V. Endocrinology 123:2762-2773 (1988)
			Young and Davis, "Efficient isolation of genes by using antibody probes," Proc. Natl. Acad. Sci. USA 80, 1194-1198 (1983)
			Dohlman, et al., Biochemistry 26, 2657-2664 (1987)
			Dolphin A.C., Trends in Neurosci. 10:53-57 (1987)
			Enjalbert A. J., Biol Chem 261:4071-4075 (1986)
			Fiers, et al., "Complete nucleotide sequence of SV40 DNA," Nature 273, 113 (1978)
			Gingrich et al., J. Biochemistry 27, 3907-3912 (1988)
			Gorman, et al., "High Efficiency DNA-Mediated Transformation of Primate Cells," Science 221, 551-553 (1983)
			Gourdi D., (1979) FEBS Letter 104:165-168
			Grandy, et al., "Cloning of the cDNA and gene for a human D2 dopamine receptor," Proc. Natl. Acad. Sci. USA 86, 9762-9766 (1989)
			Grigoriadis, FEBS Let. 227:220-224 (1988)
			Hamblin, M.N. Biochem Pharmacol 33, 877-887
			Hamblin, Life Sci 30:1587-1595 (1982)
			Hubbard & Ivatt, "Synthesis and Processing of Asparagine-Lined Oligosaccharides 1.2," Ann. Rev. Biochem 50, 555-583 (1981)
			Hytel J., Eur. J. Pharmacol 91, 153-154 (1983)
			Jarvie, et al., "Dopamine D2 Receptor Binding Subunits of Mr. @ 140,000 and 94,000 in Brian: Deglycosylation Yields a Common Unit of Mr. @ 44,000," Mol. Parmacol. 34, 91-97 (1988)
			Jones S.V.P., Proc. Natl. Acad. Sci. USA 85, 4056-4060 (1988)
			Journot L., (1987) J. Biol. Chem. 262:15106-15110
			Judd, Endocrinology 123:2341-2350 (1988)
			Kane, et al., "Clozapine for the Treatment-Resistant Schizophrenic," Arch. Gen. Psychiat. 45, 789-796 (1988)
			Karose (1983) J. Biol. Chem. 258:4870-4875
			Kebabian and Calne, "Multiple receptors for dopamine," Nature 277, 93-96 (1979)
			Kennedy, et al., "A HincII RFLP in the human D4 dopamine receptor locus (DRD4)," Nucleic Acids Research 19(20), 5801 (1991)
			Kobilka, B.K. Science 238:650-656 (1987)
			Kobilka, Nature 329:75-79 (1987)
			Koch, Eur. J. Pharmacol. 92:279-283 (1983)
			Kozak, "Compliation and analysis of sequences upstream from the translation start site in eukaryotic mRNAs," Nucleic Acid Res. 12, 857-872 (1984)
			Kubo, T. Nature 323:411-416 (1986)

			Lacey (1987) J. Physiol 392:397-416
			Law., (1988) Mol. Endocrinology 2:966-972
			Lefkowitz R. J. Biol. Chem. 263:4993-4996 (1988)
			Malgaroli, et al., J. Biol. Chem. 262:13920-13927 (1987)
			Maso Y, Nature 329:836-838 (1986)
			Maziere, et al., Life Sciences., 35:1349-1356 (1984)
			Memo M., (1986) J. Neural Trans (Suppl.) 22:19-32
			Mount, "A catalogue of splice junction sequences," Nucl. Acids. Res. 10, 461-472 (1982)
			Mullis, "The Polymerase Chain Reaction: Why It Works," in Curr. Commun. Mol. Bio., Polymerase Chain Reaction, Erlich, Bibbs & Kazazian, eds., Cold Springs Harbor Press, pp. 237-243
			Neve, Mol. Pharmacol 30, 104-111 (1986)
			Ninik, et al., Biochemistry 27, 7594-7599 (1988)
			Noonan, et al., "Quantitative Estimation of MDR1 mRNA Levels by Polymerase Chain Reaction," in Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells, Roninson eds., Plenum Publishing Corporation, 1991, pp. 319-333
			O'Dowd, et al., "Palmitoylation of the Human b2-Adrenergic Receptor," J. Biol. Chem. 264, 7564-7569 (1989)
			Ohara, (1988) Mol. Pharmacol 33:290-296
			Onali P., Mol. Pharmacol 28:138-145
			Ozawa S., (1986) Physiol Rev. 66:887-952
			Peterson G.L. Analyt Biochem 83:346-356 (1977)
			Quantitative Filter Hybridization: 5.1 Discrimination between related sequences-stringency of hybridization," 1985, in Nucleic Acid Hybridisation: A Practical Approach, Hames & Higgins, eds., IRL Press, pp. 81-82
			Salomon Y.C., Analyt Biochem 58:541-548 (1974)
			Sandoz Canada, Inc., Clozaril: Summary of preclinical and clinical data (1990)
			Sanger, et al., "DNA sequencing with chain-terminating inhibitors," Proc. Natl. Acad. Sci. USA 74 (12), 5463-5467 (1977)
			Schofield (1983) FEBS Lett 159:79-82
			Schonbrunn (1978) J. Biol. Chem. 253:6473-6483
			Schwartz, et al., J. Neurochemistry, 34 (1980) 772-778
			Seeman, et al., "Human Brain D1 and D2 Dopamine Receptor in Schizophrenia, Alzheimer's, Parkinson's, and Huntington's Diseases," Neuropsychopharm. 1, 5-15 (1987)
			Seeman, Synapse 1, 133-152 (1987)
			Sengoles, et al., "Purification and Characterization of the D2-Dopamine Receptor from Bovine Anterior Pituitary," J. Biol. Chem. 263, 18996-19002 (1988)
			Senogles, et al., Biochemistry 25, 749-753 (1986)
			Sengoles S.E., et al., J. Biol. Chem. 262, 4860-4867 (1987)

		Sibley, et al., Cell 48, 913-922 (1987)
		Simmounds S.H., Neurosci Lett. 60:267-272 (1985)
		Smithies, et al., "Insertion of DNA sequences into the human chromosomal b-globin locus by homologous recombination," Nature 317, 230-234 (1985)
		Sokoloff, et al., "Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics," Nature 347, 146-151 (1990)
		Sokoloff, et al., "Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor," European Journal of Pharmacology 225, 331-337 (1992)
		Sommer, et al., "Minimal homology requirements for PCR primers," Nucleic Acids Research 17(16), 6749 (1989)
		Strader, et al., "Conserved Aspartic Acid Residues 79 and 113 of the b-Adrenergic Receptor Have Different Roles in Receptor Function," J. Biol. Chem. 263, 10267-10271 (1988)
		Sunahara, et al., "Human dopamine D1 receptor encoded by an intronless gene on chromosome 5," Nature 347, 80-83 (1990)
		Tahijian, Meth. Enzymol. (1979) 58:526-535
		Taraskevich P.S., (1978) Nature 276, 832-834
		Thomas & Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells," Cell 51, 503-512 (1987)
		Uher, Biol Chem. 262, 15202-15207 (1987)
		Ullrich A., Science 196, 1313-1319 (1977)
		Urwyler, et al., "Identification of dopamine "D3" and "D4" binding sites, labeled with [3H] 2-amino-6, 7-dihydroxy-1, 2, 3, 4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively," Journal of Neurochemistry 46(4), 1058-1067 (1986)
		Vallar L., (1988) J. Biol. Chem. 263:10127-10134
		Van Tol, et al., "Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine," Nature 350, 610-614 (1991)
		Van Tol, et al., "Multiple Dopamine D4 Receptor Variants in the Human Population," Nature 358, 149-152 (1992)
		Weiss S. Mole Pharmacol 27:595-599 (1985)
		Zhou, et al., "Cloning and expression of human and rat D1 dopamine receptors," Nature 347, 76-80 (1990)
EXAMINER		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.